In 2017, midostaurin, one of the first FLT3 inhibitors to be studied in AML, was approved for use with induction and consolidation by the US Food and Drug Administration (FDA), as administered in the RATIFY trial, and com-bination therapy was recommended for the preferred strategy by the guidelines of the National Comprehensive Cancer Network (NCCN). The gene discussed is FLT3; the disease is acute myeloid leukemia.